Le Lézard
Classified in: Health, Science and technology
Subject: SHM

Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST


HERZLIYA, Israel and CALGARY, AB, Feb. 5, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it will provide a corporate update to the investment community and its shareholders through a Zoom livestream on February 12, 2024, at 4:00pm EST.

Innocan Pharma Corporation logo

The update will include a presentation by Innocan's CEO Iris Bincovich describing the key research milestones achieved by the Company to date.

Registration for the Zoom livestream is available here: https://us06web.zoom.us/meeting/register/tZIlf-2hrzItEtD86WAjjfbFPmtLP_Mq52iJ

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact: 
Iris Bincovich, CEO 
+1 5162104025
+972-54-3012842 
+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Logo - https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

SOURCE Innocan Pharma Corporation


These press releases may also interest you

at 08:39
SG360° Secures Elite HITRUST Certification, Enhancing Data Security Standards
SG360°, a leading provider of integrated print and addressable marketing solutions, proudly announces it has achieved the highly esteemed HITRUST r2 certification. Recognized globally as the gold standard for data security, the HITRUST r2...

at 08:37
Wild West Children's Dentistry Expands Reach to Nine Locations in Arizona, Offering Exceptional Care for All Ages and Needs
Wild West Children's Dentistry, a local family dentist in Arizona, is proud to announce its expansion to an impressive nine locations across the state. With offices now in Gilbert, Scottsdale, Glendale, Biltmore, Central Phoenix, Mesa, Phoenix, ...

at 08:37
Cinesteam® Is a Deodorizing Support Tool for Palliative Care
Palliative care is a key aspect of recovery for many patients. Unlike hospice care (which is designed to maintain comfort and quality of life for a terminally ill patient), palliative care seeks to ease discomfort during a lengthy medical procedure,...

at 08:37
Proactive Healthcare Staffing Sets the Standard for High-Quality, Compliant Care for Skilled Nursing Facilities in Washington
Proactive Healthcare Staffing, a leading medical staffing agency in Washington State, has distinguished themselves by employing 100% of its clinicians as W-2 employees rather than 1099 contractors. This strategic choice ensures enhanced quality care...

at 08:35
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
Silence Therapeutics plc ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who...

at 08:35
CLEW Expands Its Intelligent Clinical Surveillance Platform to All Inpatient Settings
CLEW, a clinical intelligence and predictive surveillance company, today announced the general availability of its FDA-cleared, AI-driven, intelligent clinical surveillance platform. Built upon proprietary, machine-learning derived prediction models...

More news about Health...


News published on and distributed by: